Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
Classical Hodgkin Lymphoma
DRUG: Tenalisib|BIOLOGICAL: Pembrolizumab
Maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL, The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment., 21 days
Maximum observed plasma concentration (Cmax), Assessment of Cmax in subjects treated with RP6530 and pembrolizumab combination, 21 days|Overall response rate (ORR) with Tenalisib and Pembrolizumab combination, No of patients with partial and complete response, 12 weeks|Duration of Response (DoR) with Tenalisib and Pembrolizumab combination, The time period from the response achieved in patient until the disease progression., 12 weeks|Progression free survival (PFS) with Tenalisib and Pembrolizumab combination, Progression-free survival was defined as the time from enrollment in the study to disease progression, 12 weeks|Conversion Rate with Tenalisib and Pembrolizumab combination, Defined as improved outcome status (i.e Improve from PR to CR or from SD to PR), 12 weeks|Proportion of patients achieving CR and PR with Tenalisib and Pembrolizumab combination, 12 weeks
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.